Sutro Biopharma (STRO) Operating Expenses (2017 - 2025)

Sutro Biopharma has disclosed Operating Expenses across 9 years of filings, most recently posting $49.7 million for Q4 2025.

• Operating Expenses for Q4 2025 came in at $49.7 million, down 37.93% year-over-year; the trailing twelve-month figure through Dec 2025 was $260.9 million (down 13.19% YoY), and the FY2025 annual result was $260.9 million, down 13.19% from the prior year.
• Operating Expenses came in at $49.7 million for Q4 2025 at Sutro Biopharma, down from $58.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $85.9 million in Q1 2025 to a low of $33.7 million in Q1 2021.
• The 5-year median for Operating Expenses is $57.2 million (2022), against an average of $58.1 million.
• Across the five-year window, Operating Expenses soared 51.87% in 2021 and slumped 37.93% in 2025, its largest moves.
• Sutro Biopharma's Operating Expenses stood at $45.7 million in 2021, then gained by 26.62% to $57.9 million in 2022, then rose by 21.98% to $70.6 million in 2023, then increased by 13.46% to $80.1 million in 2024, then tumbled by 37.93% to $49.7 million in 2025.
• The last three Operating Expenses figures came in at $49.7 million (Q4 2025), $58.2 million (Q3 2025), and $67.1 million (Q2 2025), per Business Quant data.